Helix BioPharma Corp. HBP.TO
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · TSX · Canada · helixbiopharma.com
Helix BioPharma Corp. is a Canadian clinical-stage biopharmaceutical company developing novel bio-conjugate drugs targeting cancers that overexpress CEACAM6. Its lead candidate, L-DOS47 (Tumor Defense Breaker™), is an antibody-enzyme conjugate investigated in clinical trials for non-small cell lung cancer, with additional pre-IND pipeline candidates LEUMUNA™ and GEMCEDA™.
Key ratios
ReturnOnAssets TTM -0.25
ReturnOnAssets 2025 -0.33
ReturnOnAssets 2024 -4.59
ReturnOnAssets 2023 -1.66
ReturnOnEquity TTM -0.55
ReturnOnEquity 2025 -0.67
Recent news
Helix Biopharma Corp. Announces Financial Results and Filing of Interim Financial Statements as of and for the Three- and Nine-Month Periods Ended April 30, 2026
2026-06-12 · Helix BioPharma
Helix BioPharma Corp. Announces Closing of Private Placement of Convertible Debentures
2026-06-03 · Helix BioPharma